Cardiac amyloidosis and transplantation
A Heidelberg study of 115 patients suggests that heart transplantation has become a feasible option for some people with end-stage cardiac amyloidosis.

Newsroom
Research advances, patient stories, policy work and news from the associations of the Alliance network.
A Heidelberg study of 115 patients suggests that heart transplantation has become a feasible option for some people with end-stage cardiac amyloidosis.
The first Canadian ATTR Patient Summit brings together patients, families, physicians and industry in Toronto in April 2023 to share knowledge and experience.

Since 2014, the Australian Amyloidosis Workshops have brought together researchers, clinicians and patients to improve care for all types of amyloidosis.
What is a clinical trial, why does it matter and is taking part voluntary? Answers to these questions and a short quiz to test your knowledge.
Four types of amyloidosis, four years before diagnosis, four specialists seen on average: an infographic to help raise awareness of amyloidosis.

Amy was diagnosed with amyloidosis at 52, after years of unexplained symptoms. She shares her journey and why finding a specialist doctor matters.
Test your knowledge of amyloidosis and learn more about the mechanisms of the disease with an interactive e-learning module shared by the Alliance.

A Spanish study suggests that people with ATTRv amyloidosis may develop eye problems over time, and recommends regular eye examinations for patients.

A Swedish TV programme looks at gene editing in transthyretin amyloidosis, with a patient treated in a study and the cardiologist who leads it in Umeå.
Join our mailing list and follow the work of the Amyloidosis Alliance, a few emails a year.